



Europäisches
Patentamt

European
Patent Office

Office européen
des brevets

22.06.2004

REC'D 27 JUL 2004

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterlagen stimmen mit der ursprünglich eingereichten Fassung der auf dem nächsten Blatt bezeichneten europäischen Patentanmeldung überein.

The attached documents are exact copies of the European patent application described on the following page, as originally filed.

Les documents fixés à cette attestation sont conformes à la version initialement déposée de la demande de brevet européen spécifiée à la page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

03029356.7

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk



Anmeldung Nr:
Application no.: 03029356.7
Demande no:

Anmeldetag:
Date of filing: 19.12.03
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

Biotech Tools S.A.
Rue de Ransbeek 230, Bloc V
1120 Bruxelles
BELGIQUE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

Epitope composition

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

A61K38/00

Am Anmeldetag benannte Vertragstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL
PT RO SE SI SK TR LI

Epitope composition

The present invention relates to a pharmaceutical composition and the use of the pharmaceutical composition.

5

Background of the invention

There are a large number of severe diseases based on unwanted recognition of antigens by antibodies. These diseases include allergic reactions and autoimmune diseases and antigen/antibody reactions are also responsible for graft rejections after transplantation.

10

Beside a large number of medicaments for suppression of the immune reaction or the symptoms of the diseases no satisfying causal therapy is available. Despite a large number of experiments and studies, there is still a need for new pharmaceutical compositions.

15

WO 88/10120 discloses a method of treating a T-cell mediated autoimmune disease in animals by oral or enteral administration of autoantigens, fragments of autoantigens or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease.

20

US 6,312,711 discloses a pharmaceutical and/or food composition comprising at least one of the conformational or sequential epitopes of an antigenic structure related to graft rejection, allergic reaction or autoimmune reaction together with stress protein selected from the group of stress protein GroEL, GrpE, DnaK and DnaJ.

25

Pecquet et al., in Vaccine 18 (2000) 1196 to 1202, disclose the induction of oral tolerance in mice by entrapped β -lactoglobulin. As discussed in this article, controversial results have been obtained by different groups in connection with similar studies.

30

- 2 -

Aim of the invention

The aim of the present invention is to provide a novel pharmaceutical composition designed to modify the immune response of patients towards diseases associated with an allergic or autoimmune reaction or towards graft rejection.

A further aim was to provide a composition which produces reliable and reproducible results.

Another aim is to provide a method for treatment or prevention of graft rejection, allergic reaction or autoimmune disease.

Summary of the invention

In one embodiment of the invention, the invention provides a pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

Another embodiment of the invention is the use of the composition of the invention for the treatment or prevention of graft rejection, allergic reaction or autoimmune disease or for eliciting oral tolerance and/or the induction of cells that may produce immunosuppressive cytokines, more preferably TGF-beta and/or IL-4 and/or IL-10.

25

In a further embodiment, the invention provides a process for the preparation of the pharmaceutical composition of the invention comprising the steps of

- hydrolyzing with chymotrypsin an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease to obtain at least one substance

30

- formulating the at least one substance for enteric or sublingual administration

- 3 -

Detailed description of the invention

5 The present invention provides a pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

10 Graft rejection, allergic reaction or autoimmune diseases are hypersensitivity reactions of immediate or delayed type brought about by contact in particular with an allergen (this reaction can be immediate and specific (anaphylaxis, urticarier, etc.) or delayed over time) or autoimmune diseases and disorders of the immune system of immediate or delayed type associated with graft rejections of host against graft type and a graft against host type.

15 Autoimmune diseases or disorders are a state of immunization of an individual against his or her own constituents and the phenomenon of graft rejection is a state of immunization of an individual against foreign constituents brought into contact with the patients. Typical autoimmune diseases are inter alias Systemic
20 Lupus erytematosus disease, Sjögren's disease, rheumatoid polyarthritis, as well as pathologies such as sarcoidosis and osteopenia, spondylarthritis, scleroderma, multiple sclerosis, amyotrophic lateral sclerosis, hyperthyroidism, Addison's disease, autoimmune hemolytic anemia, Crohn's disease, Goddpas-
25 ture's syndrome, Graves' disease, Hashimoto's thyroiditis, idiopathic purpural hemorrhage, insulein-dependent diabetes, myasthenia, pemphigus vulgaris, pernicious anemia, poststreptococcal glomerulonephrtitis, psoriasis and sponta-
neous sterility.

30 The term "antigenic structure" covers macromolecules such as allergens made of peptides, lipids, polysaccharides and/or nucleic acids. Typical antigenic structures are inter alias insulin, thyroglobulin, thyroid peroxidase, type II collagen, gliadin, GAD65, proteolipid protein, S-antigen, acetylcholin receptor, hapttenized

- 4 -

colonic proteins, interphotoreceptor retinoid binding protein, myelin basic protein, myelin oligodendrocyte glycoprotein, peripheral nerve P2, cytoplasmic TSH receptor, intrinsic factor, lens proteins, platelets, nucleoproteins such as histones, heat shock proteins, MHC I, MHC II, MHC-peptides complexes, milk allergens, venom allergens, egg allergens, weed allergens, grass allergens, tree allergens, shrub allergens, flower allergens, grain allergens, fungi allergens, fruit allergens, berry allergens, nut allergens, seed allergens, bean allergens fish allergens, shellfish allergens, meat allergens, spices allergens, insect allergens, mite allergens, animal allergens, animal dander allergens, allergens of Hevea brasiliensis, coagulation factors and blood group antigens.

According to the invention, the composition comprises at least one substance which is obtainable by hydrolysis of an antigenic structure, that is according to the invention not complete antigenic structure are used in the pharmaceutical composition but fragments thereof.

Surprisingly, hydrolysis with chymotrypsin provides improved pharmaceutical compositions compared to hydrolysis with pepsin or other proteases.

Such substances can either be prepared by hydrolysis but they can also be prepared by synthetic methods.

In case of an hydrolysis, the antigenic structure can be modified prior to hydrolysis either by physical e.g. heating, high mechanical pressure or by chemical methods e.g. reductive reagents (such as thioredoxin activated either by NADPH via NADP-thioredoxin-reductase or by dithiothreitol) oxidative reagents, alkylating reagents, urea, guanidinium chloride.

What is important according to the invention is that the pharmaceutical composition is prepared for sublingual or enteric administration.

"Sublingual administration" is a method wherein the substance is combined in a

- 5 -

pharmaceutical formulation which allows absorption of the at least one substance in the mouth mucosa.

5 "Enteric administration" is a pharmaceutical formulation which protects the active ingredient from absorption prior to entry into the intestine. Preferably absorption is effected in the ileum, duodenum or jejunum.

Especially suitable formulation includes coating with polymers, e.g. as sold under the trademark Eudragit®, commercially available from Degussa, Germany. Eudragit® polymers are suitable for solid oral formulations which are released in the intestine.

15 Without wishing to be bound to a theory, it is believed that former formulations of such antigenic structures were partially destroyed by the gastric juice. While this might have produced hydrolyzed fragments of the respective antigens, the amount of hydrolyzed peptides absorbed was highly dependent of the digestive activity of the patient and, therefore, it was highly variable.

20 Only with a pharmaceutical composition of the present invention, the composition can be produced with constant quality. By either sublingual or enteric administration, the amount of absorbed active ingredient can be tightly controlled.

25 It is important to identify the adequate amount for treatment or prevention of a respective diseases or disorders. Typical preferred amounts are in the range of 0.001 µg to 1000 µg per dosage unit and it is preferred that the dosage unit is 0.01 µg or more. In a more preferred embodiment, the dosage unit is 0.1 µg or more and in a very preferred embodiment, it is 1 µg or more.

30 It is also important that the amount of active ingredient is not too high. It is preferred that the amount of the at least one substance is 100 µg or less, 50 µg or less and more preferred 10 µg or less. These dosage units are calculated on the basis of a normal patient with a weight of 75 kg. Typically, 1 to 10 dosage

- 6 -

units should be applied daily.

In one preferred embodiment the at least one substance (which is the active ingredient of the pharmaceutical composition of the present invention) is obtain-
5 able by hydrolysis of a protein. In a very preferred embodiment, the at least one substances is a peptide. The molecular weight of the peptide is preferably less than 30 kDa, more preferably less than 10 kDa. The at least one substance can be obtained by hydrolysis.

10 Moreover, in a preferred embodiment, the at least one substance can bind to a heat shock protein (HSP).

In a further embodiment, the composition can comprise one or more "enhancers". Suitable enhancers are nucleoside triphosphates, nucleoside
15 diphosphates, nucleoside monophosphates, nucleic acids, peptide nucleic acids, nucleosides or analogs thereof, immunosuppressive cytokines, 1,25-dihydroxyvitamin D3 or analogs thereof, lipopolysaccharides, endotoxins heat shock proteins, thioredoxin with either NADPH and NADP-Thioredoxin reductase or dithiothreitol.

20

Other enhancers are polysaccharides, vitamins and compounds inducing expression of immunoproteasomes. A further preferred enhancer is a bacterial lysate, e.g. as described in EP 0 269 928 A2, GB 2240922 A or GB 2054374.

25 It is preferred that the pharmaceutical composition is free of heat shock proteins.

The composition of the present invention is especially useful for the treatment or prevention of graft rejection, allergic reaction or autoimmune disease. They are
30 further suitable for eliciting oral tolerance and/or the induction of cells that may produce immunosuppressive cytokines, more preferably TGF-beta and/or IL-4 and/or IL-10.

- 7 -

In a further embodiment the invention provides a process for the preparation of the composition which comprises the steps of

- 5
- hydrolyzing an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease to obtain at least one substance
 - formulating the at least one substance for enteric or sublingual administration.

As explained above, hydrolysis can be an enzymatic hydrolysis and hydrolysis
10 with chymotrypsin is especially preferred. The invention is explained in more details by the following examples.

Examples

- 15 Four groups of mice were sensibilized against β -lactoglobulin (BLG) according to the following protocol.

Chymotrypsin digestion

- 20 One milligram of BLG is dissolved in 1 mL of Tris.HCL 40 mM, 10 mM CaCl_2 pH 8.0 and 20 μL of chymotrypsin solution (final ratio protein/protease of 0.2) is added to the protein. The resulting solution is incubated at 37°C for six hours. The solution is then centrifuged through a centricon YM-10 assembly to remove the remaining protein and chymotrypsin.

25

HPLC analysis

- The low molecular weight fractions are fractionated by reverse phase high pressure liquid chromatography (HPLC) using a Vydac C18 reverse phase column
30 (HP32, 201TP52 C18, 250/2.1 mm, 5 μm). The elution of the peptides can be monitored at both OD 214 nm and OD 280 nm.

- 8 -

Figure 1: peptides (MW < or = 10 kDa) generated by chymotrypsin-cleavage of BLB

Figure 2: peptides from the chymotrypsin-cleavage of BLG (MW < or = 10 kDa) that were bound to DnaK.

5

DnaK.ATP preparation

25 µL of ATP solution (4.5 mg/mL) in buffer 1 (25 mM HEPES, 10 mM KCl, 3 mM MgCl₂, 5 mM 2-mercaptoethanol, pH 7.5) is added to 400 µL of DnaK (2 mg/mL of buffer 1). The solution is incubated at 20°C for one hour, and then is centrifuged through a centricon YM-10 assembly to remove any low molecular weight material loosely associated with Dna K. The large molecular weight fraction is removed, and washed extensively with buffer 1 by ultrafiltration using a centricon YM-10.

15

In vitro production of the compositions

The ultrafiltrated digestion is diluted in the suitable buffer 1. Then, ADP is added (1 mM final) and the mixture is incubated for one hour at 25°C

20

or the ultrafiltrated digestion is mixed with the ADP-pretreated DnaK. Then, ADP is added (1 mM final) and the mixture is incubated for one hour at 25°C in the suitable buffer 1.

Both types of compositions are further diluted in the suitable buffer 1 to give the following compositions (total doses):

- p8: 10 µg hydrolyzed BLG + 10 µg HSP
- p9: 1 µg hydrolyzed BLG + 1 µg HSP
- 30 p10: 10 µg hydrolyzed BLG
- p11: 1 µg hydrolyzed BLG
- c: control (buffer)

- 9 -

Animal studies

Four groups of mice were sensitized against BLG at days J0, J7, J14 and J21 by
5 gavage after gastric incubation with 20 mg BLG and 10 µg cholera toxin in 0.2 M
Na₂HCO₃.

The compositions are administered in 5 equivalent doses (total dose divided by
5) every two days from the first day of the treatment (J26).
10

Mice are individually treated, and oral administration is performed by buccal
injection in micro-doses of 0.012 mL.

On day 36 and 56, immunoglobulines were measured
15

Figure 3 discloses the change of IgG1.

Figure 4 discloses results for IgE.

Figure 5 discloses results for IgG2a.

Figure 6 discloses results for IgA.
20

It can be seen that the animals treated with peptides free of HSP show a re-
duced augmentation of immunoglobulines. For IgE a composition comprising
peptides alone is similar to the control group.

25 Figure 7 gives clinic scores for the different groups.

As can be seen from these data, some of the animals show a reduced clinical
score when treated with small amount of a pharmaceutical composition of the
present invention (1 µg; P 11) compared to a higher amount (10 µg; P10). This
30 study also shows that significant oral tolerance was reached when the oral dose
of peptides was lower than 10 µg. Low amounts of a pharmaceutical composition
of the present invention seems to suppress the specific humoral response to-

- 10 -

wards BLG (IgG1 and IgG2a) from days 36 to 56, whereas a pharmaceutical composition of the present invention combined with an adjuvant (HSP) induces an oral tolerance with stabilization of the IgG2a levels from days 36 to 56.

- 11 -

Claims

1. A pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.
5
2. The pharmaceutical composition of claim 1 wherein the amount of the at least one substance is in the range of 0,001 to 1000 µg, preferably 1 to 100 µg.
3. The pharmaceutical composition of claim 1 or 2 wherein the at least one
10 substance is obtainable by hydrolysis of a protein.
4. The pharmaceutical composition of any one of claim 1 to 3 wherein the at least one substance is a peptide.
5. The pharmaceutical composition of claim 4 wherein the peptide has a molecular weight of less than 30 kDa, preferably less than 10 kDa.
- 15 6. The pharmaceutical composition of any one of claim 1 to 5 comprising additionally at least one substance selected from the group of nucleoside triphosphates, nucleoside diphosphates, nucleoside monophosphates, nucleic acids, peptide nucleic acids, nucleosides or analogs thereof, immunosuppressive cytokines, compounds inducing expression of immunoproteasomes,
20 1,25-dihydroxyvitamin D3 or analogs thereof, lipopolysaccharides, endotoxins, heat shock proteins, polysaccharides, vitamins and bacterial lysates.
7. The pharmaceutical composition of any one of claim 1 to 6 wherein the antigenic structure is selected from insulin, thyroglobulin, thyroid peroxidase, type II collagen, gliadin, GAD65, proteolipid protein, S-antigen, acetylcholin
25 receptor, haptенized colonic proteins, interphotoreceptor retinoid binding protein, myelin basic protein, myelin oligodendrocyte glycoprotein, peripheral

- 12 -

- 5 nerve P2, cytoplasmic TSH receptor, intrinsic factor, lens proteins, platelets, nucleoproteins such as histones, heat shock proteins, MHC I, MHC II, MHC-peptides complexes, milk allergens, venom allergens, egg allergens, weed allergens, grass allergens, tree allergens, shrub allergens, flower allergens, grain allergens, fungi allergens, fruit allergens, berry allergens, nut allergens, seed allergens, bean allergens fish allergens, shellfish allergens, meat allergens, spices allergens, insect allergens, mite allergens, animal allergens, animal dander allergens, allergens of Hevea brasiliensis, coagulation factors and blood group antigens.
10. 8. Use of the pharmaceutical composition according to any one of claims 1 to 7 for the treatment or prevention of graft rejection, allergic reaction or autoimmune disease.
- 15 9. Use of a composition according to any one of claims 1 to 8 for eliciting oral tolerance and/or the induction of cells that may produce immunosuppressive cytokines, more preferably TGF-beta and/or IL-4 and/or IL-10.
10. A process for the preparation of the pharmaceutical composition of any one of claims 1 to 7 comprising the steps of
- 20 • hydrolyzing with chymotrypsin an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease to obtain at least one substance
- formulating the at least one substance for enteric or sublingual administration
- 25 11. A composition comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

- 13 -


Abstract

A pharmaceutical composition for sublingual or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.

5


- 1/7 -

Figure 1




- 2/7 -

Figure 2




- 3/7 -

Figure 3




- 4/7 -

Figure 4




- 5/7 -

Figure 5



- 6/7 -



Figure 6



- 7/7 -

Figure 7

Challenge J36



Challenge J56

